SequelSEC

CUMBERLAND PHARMACEUTICALS INC CPIX

Pharmaceutical Preparations · CIK 0001087294 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$31.27M
Fiscal year ended 2026-06-30
Operating income
-$9.63M
Fiscal year ended 2026-06-30
Free cash flow
$683.90K
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$29.40MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.97Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue0.9%4th
Current ratio1.01x16th
CapEx / revenue0.2%17th
R&D / revenue12.5%17th
FCF margin10.9%80th
Operating margin-6.3%76th
Gross margin85.0%74th
Net margin-6.4%72th
Revenue YoY growth17.6%64th

CUMBERLAND PHARMACEUTICALS INC (CPIX) reported revenue of $31.27M and net income of -$10.92M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from CUMBERLAND PHARMACEUTICALS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CUMBERLAND PHARMACEUTICALS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$31.27M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$9.63M
Net income-$10.92M
Research & development$5.03M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$36.66K
Diluted EPS$-0.73
Selling, general & administrativeUnavailable
General & administrative$11.71M
Selling & marketingUnavailable

Balance

CUMBERLAND PHARMACEUTICALS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$3.86M
Total assets$62.88M
Current assets$33.64M
Total liabilities$45.77M
Current liabilities$35.19M
Total equity incl. NCI$17.11M
Temporary (mezzanine) equityUnavailable
Inventory$29.94K
Accounts receivable$13.42M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$19.55M

Cash flow

CUMBERLAND PHARMACEUTICALS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$745.97K
Capital expenditures$62.07K
Investing cash flow-$5.75M
Financing cash flow-$7.22M
Net change in cash-$12.22M
Stock-based compensation$438.13K
Common dividends paidUnavailable
Common share repurchases$71.44K
Depreciation & amortization$4.14M

Derived

CUMBERLAND PHARMACEUTICALS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$683.90K
Gross marginUnavailable
Operating margin-30.8%
FCF margin2.2%
SBC / revenue1.4%
Current ratio0.96x
Revenue YoY growth-1.1%
Net margin-34.9%
R&D / revenue16.1%
CapEx / revenue0.2%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CPIX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.